Assessment of Active Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) plasma kinetics in Patients at acute stage of Ischemic Stroke: Prospective, Multicentre, Open, Non-randomised, Biomarker Study - TAFIa levels in Acute Stroke

institute de Recherches Internacionales Servier (promotor internacional)0 个研究点目标入组 37 人开始时间: 2017年8月10日最近更新: 2022年4月19日

适应症

试验速览

暂无简介。

•- Adult patients (= 18 years old) within 4.5 hours after ischemic stroke symptoms onset (or last time known normal),
•- Imaging evidence of cerebral artery occlusion in anterior circulation: proximal (internal carotid artery (ICA), middle cerebral artery M1 (MCA-M1) or distal (MCA-M2, MCA-M3) arteries,
•- Eligible for pharmacological thrombolysis alone or followed by EVT according to current clinical guidelines,
•- Complete informed consent signed (by the patient or an authorized representative according to local regulation) prior to participation in the trial or within 12 hours if an abbreviated informed consent has been signed prior to the participation in the trial (by the patient or an authorized representative according to local regulation) or orally agreed by the patient and witnessed by a person according to local regulation.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 7
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 33

•- Any known serious disease (including active malignancy, active infection) likely to interfere with the conduct of the study, according to investigator’s judgment,
•- Known pregnant or breastfeeding woman,
•- Patients unlikely to cooperate in the study,
•- Participation in another interventional study at the same time or within the past 3 months (participation in non-interventional registries or epidemiological studies is allowed).

发起方

institute de Recherches Internacionales Servier (promotor internacional)